Cargando…
Safety and Efficacy of Gammaplex® in Idiopathic Thrombocytopenic Purpura (ClinicalTrials.gov - NCT00504075)
BACKGROUND AND OBJECTIVES: This multicentre, open-label study investigated the safety and efficacy of Gammaplex, a 5% Intravenous Immunoglobulin (IVIg), in patients with idiopathic (immune) thrombocytopenic purpura (ITP). MATERIALS AND METHODS: Patients were between the ages of 6 and 70 years; had I...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043496/ https://www.ncbi.nlm.nih.gov/pubmed/24892422 http://dx.doi.org/10.1371/journal.pone.0096600 |
_version_ | 1782318915321331712 |
---|---|
author | Dash, Clive H. Gillanders, Kate R. Stratford Bobbitt, Margaret E. Gascoigne, Ernie W. Leach, Samantha J. |
author_facet | Dash, Clive H. Gillanders, Kate R. Stratford Bobbitt, Margaret E. Gascoigne, Ernie W. Leach, Samantha J. |
author_sort | Dash, Clive H. |
collection | PubMed |
description | BACKGROUND AND OBJECTIVES: This multicentre, open-label study investigated the safety and efficacy of Gammaplex, a 5% Intravenous Immunoglobulin (IVIg), in patients with idiopathic (immune) thrombocytopenic purpura (ITP). MATERIALS AND METHODS: Patients were between the ages of 6 and 70 years; had ITP for at least six months and had a platelet count ≤20×10(9)/L. Eligible patients were dosed with 1 g/kg of Gammaplex on two consecutive days, followed by assessment of safety and efficacy on Days 3, 5, 9, 14, 21, 32 and 90. Response was defined as the increase in platelet count to a threshold of ≥50×10(9)/L on or before Day 9 after the first dose of Gammaplex. RESULTS: All 35 patients received at least one infusion of Gammaplex. Twenty-nine (83%) patients responded to Gammaplex, similar to the historical control, with a 95% lower one-sided confidence interval of 68.9%. Median duration of response was 10.0 days, with an overall reduction in bleeding episodes. Gammaplex provided supranormal concentrations of total IgG; mean peak concentration (Cmax) of 45.3 g/L (4.53 g/dL), with a mean half-life of 28.5 days. Fifteen patients reported 63 Adverse Drug Reactions (ADRs); the most common were headache (10 patients), vomiting (6 patients) and pyrexia (5 patients). Five of these ADRs were considered serious, one patient had three concurrent Serious Adverse Events (SAEs); these were vomiting, dehydration and headache. Two other patients each had one SAE (headache). There were no unexpected Adverse Events (AEs) or thromboembolic episodes and no significant changes in vital signs, biochemical, haematological and virology results. Conclusion: Gammaplex achieved a very high concentration of serum IgG but was well-tolerated and effective in the treatment of ITP with a similar degree of efficacy to the pre-determined historical control group and the pre-set statistical criteria. TRIAL REGISTRATION: ClinicalTrials.gov NCT00504075 Clinical Trials Registry India 000016 |
format | Online Article Text |
id | pubmed-4043496 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-40434962014-06-09 Safety and Efficacy of Gammaplex® in Idiopathic Thrombocytopenic Purpura (ClinicalTrials.gov - NCT00504075) Dash, Clive H. Gillanders, Kate R. Stratford Bobbitt, Margaret E. Gascoigne, Ernie W. Leach, Samantha J. PLoS One Research Article BACKGROUND AND OBJECTIVES: This multicentre, open-label study investigated the safety and efficacy of Gammaplex, a 5% Intravenous Immunoglobulin (IVIg), in patients with idiopathic (immune) thrombocytopenic purpura (ITP). MATERIALS AND METHODS: Patients were between the ages of 6 and 70 years; had ITP for at least six months and had a platelet count ≤20×10(9)/L. Eligible patients were dosed with 1 g/kg of Gammaplex on two consecutive days, followed by assessment of safety and efficacy on Days 3, 5, 9, 14, 21, 32 and 90. Response was defined as the increase in platelet count to a threshold of ≥50×10(9)/L on or before Day 9 after the first dose of Gammaplex. RESULTS: All 35 patients received at least one infusion of Gammaplex. Twenty-nine (83%) patients responded to Gammaplex, similar to the historical control, with a 95% lower one-sided confidence interval of 68.9%. Median duration of response was 10.0 days, with an overall reduction in bleeding episodes. Gammaplex provided supranormal concentrations of total IgG; mean peak concentration (Cmax) of 45.3 g/L (4.53 g/dL), with a mean half-life of 28.5 days. Fifteen patients reported 63 Adverse Drug Reactions (ADRs); the most common were headache (10 patients), vomiting (6 patients) and pyrexia (5 patients). Five of these ADRs were considered serious, one patient had three concurrent Serious Adverse Events (SAEs); these were vomiting, dehydration and headache. Two other patients each had one SAE (headache). There were no unexpected Adverse Events (AEs) or thromboembolic episodes and no significant changes in vital signs, biochemical, haematological and virology results. Conclusion: Gammaplex achieved a very high concentration of serum IgG but was well-tolerated and effective in the treatment of ITP with a similar degree of efficacy to the pre-determined historical control group and the pre-set statistical criteria. TRIAL REGISTRATION: ClinicalTrials.gov NCT00504075 Clinical Trials Registry India 000016 Public Library of Science 2014-06-03 /pmc/articles/PMC4043496/ /pubmed/24892422 http://dx.doi.org/10.1371/journal.pone.0096600 Text en © 2014 Dash et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Dash, Clive H. Gillanders, Kate R. Stratford Bobbitt, Margaret E. Gascoigne, Ernie W. Leach, Samantha J. Safety and Efficacy of Gammaplex® in Idiopathic Thrombocytopenic Purpura (ClinicalTrials.gov - NCT00504075) |
title | Safety and Efficacy of Gammaplex® in Idiopathic Thrombocytopenic Purpura (ClinicalTrials.gov - NCT00504075) |
title_full | Safety and Efficacy of Gammaplex® in Idiopathic Thrombocytopenic Purpura (ClinicalTrials.gov - NCT00504075) |
title_fullStr | Safety and Efficacy of Gammaplex® in Idiopathic Thrombocytopenic Purpura (ClinicalTrials.gov - NCT00504075) |
title_full_unstemmed | Safety and Efficacy of Gammaplex® in Idiopathic Thrombocytopenic Purpura (ClinicalTrials.gov - NCT00504075) |
title_short | Safety and Efficacy of Gammaplex® in Idiopathic Thrombocytopenic Purpura (ClinicalTrials.gov - NCT00504075) |
title_sort | safety and efficacy of gammaplex® in idiopathic thrombocytopenic purpura (clinicaltrials.gov - nct00504075) |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043496/ https://www.ncbi.nlm.nih.gov/pubmed/24892422 http://dx.doi.org/10.1371/journal.pone.0096600 |
work_keys_str_mv | AT dashcliveh safetyandefficacyofgammaplexinidiopathicthrombocytopenicpurpuraclinicaltrialsgovnct00504075 AT gillanderskater safetyandefficacyofgammaplexinidiopathicthrombocytopenicpurpuraclinicaltrialsgovnct00504075 AT stratfordbobbittmargarete safetyandefficacyofgammaplexinidiopathicthrombocytopenicpurpuraclinicaltrialsgovnct00504075 AT gascoigneerniew safetyandefficacyofgammaplexinidiopathicthrombocytopenicpurpuraclinicaltrialsgovnct00504075 AT leachsamanthaj safetyandefficacyofgammaplexinidiopathicthrombocytopenicpurpuraclinicaltrialsgovnct00504075 |